|
|
Archive of Past Events
| |
Archived Presentations
Events in 2011-2012:
Visit "Meetings and Seminars" for complete schedule of the TRIG-hosted events and abstracts of lectures.
NIH Translational Research Interest Group Lecture Series
June 14, 2012 (Thursday) 9-10:30 a.m., Bldg. 10 Room 2-C116
Zhong Chen, MD, PhD
Staff Scientist, Chief of Clinical Genomics Unit, Head and Neck Surgery Branch, NIDCD
“Protein Kinase CK2 as an Emerging Target Using Antisense Nanoparticles and Small Chemical Drug Inhibitor”
TRIG End of Year Meeting
Direction to Bldg. 10 Room 2C-116: From Lipsett Amphitheater, head North, through double doors, make an immediate turn right, through the door, then up the stairs to the second floor. Take a right, and the room is on your right.
*********************************************************
May 10, 2012 (Thursday) 1-2 p.m., Bldg. 50 Room 1227/1233 Lobby
Kenneth A. Jacobson, PhD
Chief, Laboratory of Bioorganic Chemistry; Chief, Molecular Recognition Section, NIDDK
“A3 Adenosine Receptor Modulators: Structure-Based Design and Application to Inflammatory Disease, Glaucoma, Ischemia, and Cancer”
*********************************************************
April 12, 2012 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Thomas E. Wellems, MD, PhD
NIH Distinguished Investigator;
Chief, Laboratory of Malaria and Vector Research, NIAID;
Elected Member, U.S. National Academy of Sciences;
Elected Member, Institute of Medicine of the U.S. National Academies
“Drug-resistant Malaria: Determinants of Treatment Outcome and Prospects for Control”
*********************************************************
March 8, 2012 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Irwin M. Arias, MD
Senior Scientist, Head, Unit of Cellular Polarity, Cell Biology and Metabolism Branch, NICHD;
Coordinator of the NIH “Demystifying Medicine” Course;
Professor of Medicine (Emeritus), Albert Einstein College of Medicine;
Professor/Chairman of Cellular and Molecular Physiology (Emeritus) and Professor of Medicine, Tufts University School of Medicine
“Serendipity and Journeys through the Hepatocyte”
*********************************************************
February 16, 2012 (Thursday) 1-2 p.m., Bldg. 50 Room 1227/1233 Lobby
Shioko Kimura, PhD
Head, Endocrinology Section, Laboratory of Metabolism, NCI
“Anti-inflammatory, growth factor and anti-fibrotic activities of Secretoglobin (SCGB) 3A2: Possible clinical applications”
*********************************************************
January 12, 2012 (Thursday) 1-2 p.m., Bldg. 50 Room 1227/1233 Lobby
Daphne W. Bell, PhD
Head, Reproductive Cancer Genetics Section, Cancer Genetics Branch, NHGRI
Recipient of the 2007 Presidential Early Career Award for Scientists and Engineers
“The Genetics and Genomics of Clinically Aggressive Endometrial Cancers: Searching for new therapeutic targets”
*********************************************************
December 8, 2011 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Daniel Kastner, MD, PhD
Scientific Director, Division of Intramural Research, NHGRI
NIH Distinguished Investigator, Medical Genetics Branch, NHGRI
“Cutting Gordian Knots at the Pools of Bethesda: Adventures in the Genomics of Inflammation”
*********************************************************
Forum on “NIH Resources for Discovery and Development of Therapeutic Candidates”
November 3, 2011 (Thursday) 1:00-3:45 p.m., Bldg. 10 Lipsett Amphitheater
Minkyung (Min) Song, PhD
Program Director, Division of Cancer Treatment and Diagnosis, NCI
"Introduction"
Christopher P. Austin, MD
Director, NIH Center for Translational Therapeutics
“Translational Therapeutics Development at NIH”
Ajay Pillai, PhD
Program Director, Computational Science, NHGRI
“Overview of Chemical Biology Databases with Focus on Using Molecular Libraries Data”
James P. Boyce, PhD
Program Officer, Division of Microbiology and Infectious Diseases, NIAID
“Resources for the Microbiology and Infectious Disease Research Community”
Jill Heemskerk, PhD
Program Director, Office of Translational Research, NINDS
“Blueprint Neurotherapeutics: A Virtual Pharma Model”
Robert DeChristoforo, RPh, MS, FASHP
Chief, Clinical Center Pharmacy Department, CAPT USPHS (Ret.), CC
“Clinical Center Pharmacy's Role in the Repurposing of Drugs”
Peter Herscovitch, MD
Director, Positron Emission Tomography Department, CC
“Positron Emission Tomography Resources for Drug Discovery and Development”
Harvey G. Klein, MD
Chief, Department of Transfusion Medicine, CC
“Cell Processing Facilities Supporting Transfusion and Regenerative Medicine”
Barbara Mroczkowski, PhD
Special Assistant, Office of the Director, Division of Cancer Treatment and Diagnosis, NCI
“NCI Experimental Therapeutics (NExT) Program”
Shivaani Kummar, MD
Head, Developmental Therapeutics Clinic, NCI
“Clinical Development of Therapeutic Candidates at NCI”
Sheryl Ruppel
Director of Regulatory Affairs, Biopharmaceutical Development Program, SAIC-Frederick Inc., NCI-Frederick
“Regulatory Requirements and Resources for Getting to an Investigational New Drug (IND) Filing with the FDA”
*********************************************************
2011 NIH Research Festival
October 24, 2011 (Monday) 2:00-4:00 p.m.
Natcher Conference Center Room E1/E2
Symposium on "Advances in Immune Targeted Therapies"
Co-Chairs: Liliana Guedez, PhD, NCI, and Shaden Kamhawi, PhD, NIAID
Immunology-based technologies have significantly contributed to the development of therapies modulating the immune system. It is timely to discuss transfer of genetically modified T-cells, vaccines, genetically engineered antibodies and interleukins as some of the promising fronts in the war against many diseases. This symposium topic is of broad interest to NIH intramural investigators who have been leaders in the development and translational research of targeted immune therapeutics. As the results from clinical trials are provided, new and unexpected information is revealed as well as some mechanistic differences between pre-clinical models and humans are reported. This symposium will serve as a scientific platform to exchange cutting-edge clinical information on issues related to the immunotherapies, to know about the challenges encountered in the clinic, and to discuss experimental approaches on how to improve the clinical translation of therapies modulating the immune system.
Program
Nicholas Restifo, MD, NCI
"Recent Developments in T-cell Adoptive Immunotherapy for Cancer Treatment"
Ravi A. Madan, MD, NCI
"Therapeutic Cancer Vaccines Combined with Standard Therapies in the Treatment of Human Carcinoma"
Alan Wayne, MD, NCI
"Bench to Bedside Development of anti-CD22 Immunotoxins for Childhood Acute Lymphoblastic Leukemia"
Bibiana Bielekova, MD, NINDS
"Clinical Translation of Daclizumab for the Treatment of Multiple Sclerosis"
Joanna Fares, NCI, FARE Award Winner
"Modulation of Myeloid-Derived Dendritic Cell Maturity: Unmasking a Novel Role for the Tumor Suppressor p15Ink4b in Immunity"
***************************************************
2011 NIH Research Festival
October 24, 2011 (Monday) 2:00-4:00 p.m.
Natcher Conference Center Balcony A
Symposium on "Informing Therapeutic Interventions with Mechanism-Based Pharmacology and Toxicology"
Co-Chairs: Minkyung (Min) Song, PhD, NCI, and Juan Lertora, MD, PhD, CC
It is essential to translate mechanisms of drug action and toxicity into efficient discovery and development of safe and effective therapeutics. Elucidation of molecular mechanisms underlying disease pathogenesis and differential responses to drugs in individual patients will inform rational development of therapeutic interventions. Such research efforts will allow scientists to contribute to reducing late-stage drug attrition due to unanticipated toxicity or lack of clinical efficacy. During this symposium, the speakers will discuss:
• Mechanism-based repurposing of an agent for potential treatment of various liver diseases;
• Development of therapeutic strategies and novel bioactive substances by understanding molecular pharmacology and toxicology of candidate agents;
• Mechanisms of microbial drug resistance within the host;
• Incorporation of molecular characteristics and biological functions of therapeutic targets during the discovery of drug candidates;
• Identification of somatic activating mutations in the disease pathway to inform targeted therapies; and
• Use of positron emission tomography tracers as molecular imaging probes to guide the development of therapeutic interventions.
Program
Bela Horvath, MD, PhD, NIAAA, FARE Award Winner
"Role of Poly (ADP-Ribose) Polymerase 1 (PARP-1) in Liver Injury, Inflammation and Fibrosis"
William D. Figg, PharmD, NCI
"Bench to Bedside and Back to the Bench: Development of Novel Therapeutic Agents"
June Kwon-Chung, PhD, NIAID
"The Relationship between Cryptococcal Adaptation to Azole Drugs and Azole Therapy Failure"
Kenneth A. Jacobson, PhD, NIDDK
"Therapeutic Interventions Based on G Protein-Coupled Receptors for Extracellular Nucleosides and Nucleotides"
Daphne W. Bell, PhD, NHGRI
"Somatic Activating Mutations in the PI3K Pathway Informing Targeted Therapies of Endometrial Cancer"
Robert B. Innis, MD, NIMH
"Positron Emission Tomography: A Tool to Study Pathophysiology and to Facilitate Therapeutic Drug Development"
*********************************************************
NIH Translational Research Interest Group Lecture Series
October 6, 2011 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Issam Zineh, PharmD, MPH, FCCP
Associate Director for Genomics, Office of Clinical Pharmacology;
Co-Director, Biomarker Qualification Program, Office of Translational Sciences
Center for Drug Evaluation and Research, Food and Drug Administration
"Pharmacogenomics from Promise to Policy"
*********************************************************
September 15, 2011 (Thursday) 1-2 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Hamilton Moses, III, MD
Chairman, The Alerion Institute; Adjunct Professor in Neurology, Johns Hopkins School of Medicine
"What is the Role of Biomedical Research in the 21st Century?"
*************************************************
Events in 2010-2011:
Abstracts of lectures are available in "Meetings and Seminars".
NIH Director's Lecture Series: First Marshall Nirenberg Lecture
May 20, 2011 (Friday) 11:30 a.m.-12:30 p.m., Bldg. 10 Masur Auditorium
Eric S. Lander, PhD
President & Director, Broad Institute of Harvard and MIT; Professor of Biology, Massachusetts Institute of Technology; Professor of Systems Biology, Harvard Medical School
"From the 'Genetic Code' to the 'Genetic Code'" (archived at http://videocast.nih.gov/summary.asp?file=16668&bhcp=1)
*************************************************
NIH Bench-to-Bedside Awardees Lecture Series
May 5, 2011 (Thursday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Mike Iadarola, PhD, NIDCR
"New approaches to pain control using agonists and allosteric modulators of TRPV1, a key peripheral integrator of pain and inflammation"
Ann C.M. Smith, MA, DSc (hon), CGC, NHGRI
"A Hard Day's Night: Treatment of the Circadian Sleep Disturbance in Smith-Magenis Syndrome"
Please visit http://www.cc.nih.gov/ccc/btb/lectures.html for more information.
**************************************************
NIH Bench-to-Bedside Awardees Lecture Series
April 8, 2011 (Friday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Alan S. Wayne, MD, NCI
"Bench to Bedside Development of Novel Therapies for Childhood Acute Lymphoblastic Leukemia"
Deborah Persaud, MD, Johns Hopkins University School of Medicine
"Therapeutic HIV Vaccines' Effects on Viral Reservoirs"
Please visit http://www.cc.nih.gov/ccc/btb/lectures.html for more information.
**************************************************
NIH Bench-to-Bedside Awardees Lecture Series
March 22, 2011 (Tuesday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Jack A. Yanovski, MD, PhD, NICHD
"Behavioral Phenotyping in Pediatric Obesity"
Gregory J. Kato, MD, NHLBI
"Vasculopathy in Sickle Cell Disease: Pathways and Treatment Trials"
Please visit http://www.cc.nih.gov/ccc/btb/lectures.html for more information.
***************************************************
NIH Translational Research Interest Group Seminar Series
February 22, 2011 (Tuesday) 1-3 p.m., Bldg. 50 Room 1227/1233 Lobby
Jeffrey A. Toretsky, MD, Georgetown University, Lombardi Comprehensive Cancer Center
"YK-4-279 is a novel small molecule directly targeting EWS-FLI1"
Jacek Capala, PhD, DSc, NCI
"Molecular Targeting of HER2 for Diagnosis and Therapy of Cancer: A Step towards Individualized Medicine"
****************************************************
NIH Translational Research Interest Group Seminar Series
January 25, 2011 (Tuesday) 1-3 p.m., Bldg. 50 Room 1227/1233 Lobby
Tiffany Wallace, PhD, NCI
"An interferon-related gene signature for poor outcome is prevalent in African-American breast and prostate cancer patients"
Leon J. Nesti, MD, PhD, NIAMS & Walter Reed Army Medical Center
"Cellular and Molecular Events in Post-Traumatic Heterotopic Ossification"
****************************************************
NIH Translational Research Interest Group Seminar Series
January 13, 2011 (Thursday) 1-3 p.m., Bldg. 50 Room 1227/1233 Lobby
Yves Pommier, MD, PhD, NCI
“Non-camptothecin topoisomerase I inhibitors: the indenoisoquinolines”
Antonio Tito Fojo, MD, PhD, NCI
“Inferring the mechanism of action of microtubule targeting agents act by knowing how they can't function”
****************************************************
NIH Translational Research Interest Group Seminar Series
November 9, 2010 (Tuesday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Steven A. Rosenberg, MD, PhD, NCI
"The Development of Immunotherapy and Gene Therapy for Cancer"
James J. Cimino, MD, NIH Clinical Center
"What is Translational about the Biomedical Translational Information Syatem: Data Repurposing at the NIH"
****************************************************
NIH Bench-to-Bedside Awardees Lecture Series
October 29, 2010 (Friday) 1-3 p.m., Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
Frank Maldarelli, MD, PhD, NCI
“Persistent HIV Viremia during Combination Antiretroviral Therapy: Implications for Viral Eradication Strategies”
Peter D. Burbelo, PhD, NIDCR
“Antibody Profiling for Disease Diagnosis and Symptoms Research”
Please visit http://www.cc.nih.gov/ccc/btb/lectures.html for more information.
****************************************************
NIH Bench-to-Bedside Awardees Lecture Series
October 14, 2010 (Thursday) 1-3 p.m., Bldg. 50 Room 1227/1233 Lobby
Robert G. Nelson, MD, PhD, National Institute of Diabetes and Digestive and Kidney Diseases, NIH
“Diabetic Kidney Disease in the Pima Indians: A Report from the Bedside”
Matthias Kretzler, MD, University of Michigan
“Systems Biology of Diabetic Nephropathy: A Report from the Bench”
Please visit http://www.cc.nih.gov/ccc/btb/lectures.html for more information.
****************************************************
2010 NIH Research Festival
Opening Plenary Session
"DNA Unwound: The Path from Characterization to Treatment of Rare and Common Genetic-based Disorders"
Co-Chairs: Dr. Richard Leapman, NIBIB, and Dr. Richard Nakamura, NIMH
October 5, 2010 (Tuesday) 9:00-11:30 a.m.
Building 10, Masur Auditorium
Christopher P. Austin, MD, National Human Genome Research Institute (one of eight speakers)
"Translational Therapeutic Development for Rare and Neglected Diseases"
****************************************************
2010 NIH Research Festival
Symposium on "Drug Repurposing at the NIH"
Co-Chairs: Dr. Craig Thomas, NHGRI, and Dr. Minkyung (Min) Song, NCI
October 6, 2010 (Wednesday) 9:00-11:00 a.m.
Natcher Conference Center Conference Room F1/F2
Recent advances in molecular analysis technologies and bioinformatics have allowed investigators to discover additional targets and pathways that are associated with diseases. Investigational agents, including those previously evaluated in the clinic but shelved due to various reasons, and approved therapeutic interventions could now be used to treat diverse diseases, including rare and neglected diseases, that share common targets and pathways. During this symposium, the NIH investigators will discuss their pioneering, drug repurposing research that allows the development of new indications, new formulations, or new combinations of available agents. Through the drug repurposing efforts, proof-of-concept studies during translational and clinical research would be substantially advanced. These efforts would undoubtedly result in an increased number of therapeutic choices for individual patients. Organizations at the NIH including the NIH Center for Translational Therapeutics and the Chemical Biology Consortium are actively engaging NIH scientists to expand these efforts.
Program
George Lountos, PhD, NCI/CCR, FARE Award Winner
"Structure-Assisted Design of Novel Inhibitors of Checkpoint Kinase 2, A Drug Target for Cancer Therapy"
Amanda J. Law, PhD, NIMH
"Genetic Regulation of NRG1/ErbB4-PI3K Signaling: Novel Therapeutic Options for Schizophrenia"
David Fitzgerald, PhD, NCI
"Overcoming Immunotoxin-treatment Barriers with ABT-263 and CP-690,550"
Noel Southall, PhD, NHGRI
"The NCTT Pharmaceutical Collection: A Focused Library of Small Molecule Drugs Enabling Rare Disease Repurposing"
Carlos A. Zarate, MD, NIMH
"Raising the Bar in for the Treatment of Depression: Modulation of Glutamatergic Receptors Leads to Antidepressant Response in Hours instead of Weeks"
Nigel H. Greig, PhD, NIA
"Exendin-4, Type 2 Diabetes and Neurodegenerative Disorders: Overlapping Mechanisms May Provide Common Treatment"
***************************************************
2010 NIH Research Festival
Symposium on "Use of Molecular Profiles and Biomarkers in Translational Research"
Co-Chairs: Dr. David S. Goldstein, NINDS, and Dr. Minkyung (Min) Song, NCI
October 6, 2010 (Wednesday) 1:00-3:00 p.m.
Natcher Conference Center Conference Room E1/E2
Advances in “–omics” technologies, bioinformatics, and epidemiology have allowed biomedical research investigators to identify clinically relevant molecular profiles and biomarkers. In this symposium, speakers will discuss the use of molecular signatures and biomarkers in understanding mechanisms of diseases and their tissue-specific subtypes; identifying common pathways to diseases; diagnosing diseases and clinical symptoms; predicting responses of patients to targeted therapies; tracking natural history; and exploring molecular mechanisms underlying effects of therapies. Molecular profiles and biomarkers are key tools for bridging basic, preclinical, and clinical research.
Program
Yi Ping Fu, PhD, NCI, FARE Award Winner
"NOTCH2 in Breast Cancer: Association of SNP rs11249433 with Gene Expression in ER-positive Breast Tumors without TP53 Mutations"
David S. Goldstein, MD, PhD, NINDS
"Biomarkers and Mechanisms of Loss of Catecholaminergic Neurons in Parkinson Disease and Related Disorders"
Electron Kebebew, MD, FACS, NCI
"Clinical Application of Transcriptome Profiling of Adrenal Neoplasm"
Zhong Chen, MD, PhD, NIDCD
"Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer"
Terrance P. O’Hanlon, PhD, NIEHS
"Proteomic and Gene Expression Arrays Suggest Common Altered Pathways in Multiple Autoimmune Diseases"
Christina M. Annunziata, MD, PhD, NCI
"NF-kappaB Signaling in Cancer: Deregulation and Targeting"
*******************************************
Events in 2009-2010:
NIH Wednesday Afternoon Lecture Series on May 26, 2010, 3:00-4:00 p.m.
Bldg. 10 (Clinical Research Center) Masur Auditorium
Daniel A. Haber, M.D., Ph.D.
Director, Massachusetts General Hospital Cancer Center
Professor, Harvard Medical School
Investigator, Howard Hughes Medical Institute
Member, Institute of Medicine
"Interrogating Circulating Tumor Cells to Direct Targeted Cancer Therapies" (archived at http://videocast.nih.gov/Summary.asp?File=15919)
****************************************************
TRIG Seminar Series on May 13, 2010
Andrea Lisco, M.D., Ph.D., NICHD
"A New Use for an Old Drug: Discovery and Implications of the Anti-HIV Activity of Acyclovir"
************************************************
TRIG Special Lecture on April 26, 2010
John I. Gallin, M.D., Director, NIH Clinical Center
"The Pipeline of Clinical Research from Bench to Bedside and Back" (archived at http://videocast.nih.gov/summary.asp?Live=8704)
************************************************
TRIG Seminar Series on March 11, 2010
Elise C. Kohn, M.D., NCI
"Molecular therapeutics in oncology: our experience with targets and targeted agents"
************************************************
TRIG Special Lecture on February 26, 2010
Alan N. Schechter, M.D., NIDDK
"Is the US model for biomedical research still working?"
************************************************
TRIG Seminar Series on January 14, 2010
Kevin Camphausen, M.D., NCI
"Translational Radiation Oncology"
***********************************************
TRIG Seminar Series on December 10, 2009
Jim Vaught, Ph.D., National Cancer Institute
"Research & Policy Initiatives in NCI's Office of Biorepositories & Biospecimen Research" (1 MB, 47-page presentation)
***********************************************
NIH Conference
December 4, 2009, 9:00 a.m.-12:00 p.m.
Bldg. 10 (Clinical Research Center) Lipsett Amphitheater
"Clinical and Translational Science Awards Pharmaceutical Assets Portal: Matching Academia and Industry for Drug Repositioning" (archived, 2-hour video from http://videocast.nih.gov)
***************************************************
TRIG Seminar Series on October 8, 2009
Yong Yao, Ph.D., National Institute of Mental Health
"Funding Opportunity: Assays for High-Throughput Screening in the Molecular Libraries Probe Production Centers Network" (700K, 16-page PDF)
Anthony Jackson, National Institute of Neurological Disorders and Stroke
"NIH Rapid Access to Intervention Development (NIH-RAID)" (100K, 13-page PDF)
****************************************************
TRIG Seminar Session on May 7, 2009
George Uhl, M.D., Ph.D., National Institute on Drug Abuse
"Translating Smoking Cessation Genetics into Practice"
Andrew N. Freedman, Ph.D., National Cancer Institute
"Pharmacogenomics Translation: From Discovery to Confirmation to Clinical Utility"
****************************************************
TRIG Seminar Session on April 9, 2009
Shivaani Kummar, M.D., National Cancer Institute
"Phase 0 Clinical Trials: A New Paradigm for Drug Development in Oncology"
Robert J. Kinders, Ph.D., National Cancer Institute
"Poly-ADP Ribose (PAR) Assay Validation and Marker Qualification for Clinical Studies"
****************************************************
2008 NIH Research Festival
The TRIG hosted a symposium during the 2008 NIH Research Festival , "Bridging the Gap between Research Discoveries and Clinical Evaluation" (Chair: Minkyung Song, PhD, NCI). In order to improve public health, the NIH Roadmap initiatives are accelerating the translation of scientific discoveries into practical applications. Significant advances in basic science research, molecular analysis technologies, bioinformatics, and validated procedures for collecting and storing high-quality clinical specimens have occurred in recent years. Enormous amounts of data, information, and resources are available for physician scientists and basic research scientists to work together to correlate laboratory data with clinical observations. Efforts are being made to improve and expedite the therapeutics development process by intelligently closing the gap between research discoveries and clinical practice, to ultimately benefit patients.
During this mini-symposium, speakers discussed the following topics:
- Improvement of preclinical models by translating clinical research and epidemiological data on the use of non-steroidal anti-inflammatory drugs in Alzheimer’s disease;
- The application of laboratory discoveries to proof-of-concept clinical studies in kidney cancer;
- Translational research on autoinflammatory diseases;
- A personalized genomics project featuring collaboration among NIH Institutes;
- Discovery and clinical evaluation of genetic and proteomic biomarkers of head and neck cancer for assessment of response to therapies, recurrence, and survival in collaboration with extramural cooperative groups
Program
Francesca Bosetti, PhD, NIA
"COX Inhibition in Neuroinflammation: Neuroprotective or Neurotoxic? Lessons from Animal Models"
W. Marston Linehan, MD, NCI
"The Genetic Basis of Kidney Cancer: Opportunity for Disease Specific Therapy"
Raphaela Goldbach-Mansky, MD, NIAMS
"The Role of IL-1 in Neonatal Onset Multisystem Inflammatory Disease (NOMID) and Other Autoinflammatory Diseases"
Leslie Biesecker, MD, NHGRI
"The ClinSeq Study: Developing a Model for Translational Genomics"
Carter Van Waes, MD, PhD, NIDCD
"The Nuclear Factor kappaB Transcriptome and Proteome in Targeted Therapy of Head and Neck Cancer"
****************************************************
TRIG Seminar Session on September 15, 2008
Wendy B. Smith, Ph.D., Office of Science Policy, Office of the Director
"The NIH Public-Private Partnership Program: Opportunities for Clinical and Translational Research"
Craig J. Thomas, Ph.D., National Human Genome Research Institute
"Translational Research and the NIH Chemical Genomics Center"
****************************************************
Inaugural Meeting of TRIG on May 29, 2008
Richard G. Wyatt, M.D., Office of Intramural Research, Office of the Director
"Challenges of Translational Research at the NIH"
Douglas M. Sheeley, Sc.D., National Center for Research Resources
"Introduction to the Clinical and Translational Science Award (CTSA) Program"
|
|
|
|